Phys Clinical Cases · renal
Renal Cell Carcinoma AND Urothelial Malignancy — DCE Clinical Case
DCE long-case and short-case station for Renal Cell Carcinoma AND Urothelial Malignancy.
On this page & tools
Target exams
Renal Cell Carcinoma AND Urothelial Malignancy — Clinical Case
DCE Long Case
Patient brief
Patient: A middle-aged or older adult with multimorbidity and a presentation centred on Renal Cell Carcinoma AND Urothelial Malignancy. [1]
Presenting complaint: Subacute or acute symptoms referable to Renal Cell Carcinoma AND Urothelial Malignancy, with enough detail to force prioritisation. [1] [2]
Past history: Common cardiometabolic and organ comorbidities that interact with the plan. [2]
Medications: A polypharmacy list that includes at least one interaction or dosing issue. [2]
Examination: Key positives and critical negatives for dangerous differentials. [1]
Investigations: A small set of results that change management. [1] [2]
Tasks
- Present a prioritised problem list. [1]
- Defend investigations and immediate therapy. [1] [2]
- Provide safety-net and follow-up advice. [2]
Model discussion points
- Working diagnosis and acuity. [1]
- Differentials and discriminators. [2]
- Treatment sequence and monitoring. [1] [2] [3]
- Multimorbidity and communication. [2]
Short case
Focused examination or counselling station linked to Renal Cell Carcinoma AND Urothelial Malignancy, with one interpretation task and one shared-decision point. [1] [2]
References
- [1]Chen YS, Yu CC, Chang R, Wu SH, et al. Efficacy of checkpoint inhibitors in genitourinary cancers with advanced chronic kidney disease Cancer Immunol Immunother, 2026.PMID 42426360
- [2]Petrelli F, Colombo Zefinetti L, D'Alessio A, Dottorini L, et al. Next-Generation Checkpoint Combinations: Optimizing PD-(L)1-Based Therapy Across the Advanced, Adjuvant, and Neoadjuvant Settings Curr Oncol Rep, 2026.PMID 42406187
- [3]Zhang Y, Wu G, Sun F, Wang B, et al. Radiomics and deep learning in upper tract urothelial carcinoma: advancing preoperative risk stratification and clinical decision-making Front Oncol, 2026.PMID 42404222
- [4]Jost LM, Duwe G, Kauth V, Höfner T, et al. [Artificial intelligence as decision support tool in urological oncology: current evidence and challenges] Urologie, 2026.PMID 42126599
- [5]Inoue S, Tsuboi I, Miszczyk M, Miyajima K, et al. Time-of-Day Immunotherapy Administration and Outcomes in Advanced Cancers: A Systematic Review and Meta-Analysis JAMA Netw Open, 2026.PMID 42084869
- [6]Maráz A, Koroncziová K, Rozsvai T [Immunotherapy for urological cancers in 2025] Magy Onkol, 2025.PMID 41385769
- [7]Xi Y, Yao T, Zhang C, Zhuang T Effectiveness of safety care and clinical nursing pathway in patients undergoing cardiovascular intervention: a randomized controlled trial Perioper Med (Lond), 2026.PMID 42469924
- [8]Marks FJ, Walters SJ, Sutton L, Jacques RM What statistical methods are more appropriate for predicting recruitment at the design stage of a randomised controlled trial? Trials, 2026.PMID 42469922